The candidiasis drugs market will register a CAGR of almost 4% by 2023

Friday, February 8, 2019 Drug News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, Feb. 7, 2019 /PRNewswire/ -- About this marketAdvances in diagnosis of antifungal resistant pathogens to

drive market growth. Although the currently available antifungal drugs are killing various species of candidiasis, some fungi can develop the ability to defend these drugs. For instance, Candida auris, an emerging antifungalČresistant yeast, is frequently
resistant to multiple antifungal drugs that were used to treat Candida infections. Moreover, it can cause serious bloodstream infections in hospitalized patients. Hence, advanced technologies are required for the diagnosis of such fungal diseases caused by antifungalČresistant pathogens. Technavio' s analysts have predicted that the candidiasis drugs market will register a CAGR of almost 4% by 2023.Read the full report: https://www.reportlinker.com/p05731033 Market OverviewRising awareness about candidiasisThe signs and symptoms of candidiasis are very broad, and they also depend on the type of candidiasis infection. They sometimes resemble the symptoms of other diseases caused by bacteria. Hence, confirmatory diagnosis methods are required to confirm the disease after assessing the initial symptoms. Early detection can aid in treating them more effectively. Therefore, to create awareness about the disease and treatment options and avoid delay in diagnosis, the CDC is providing information about candidiasis, and its causes, risk factors, transmission, diagnosis, and treatment in the US.Side effects of available drugs Although several off-label medications are available for the symptomatic treatment of candidiasis, the side effects associated with them are decreasing their preference. For instance, polyene antifungal medicine, nystatin causes mouth irritation, diarrhea, nausea, vomiting, stomach upset, rashes, hives, and skin irritation. Although azole medications such as fluconazole, voriconazole, and miconazole are usually well tolerated, they cause side effects such as a headache, nausea, abdominal pain, diarrhea, vomiting, dyspepsia, liver damages, and rashes.For the detailed list of factors that will drive and challenge the growth of the candidiasis drugs market during the 2019-2023, view our report.Competitive LandscapeThe market appears to be fragmented and with the presence of several companies including Merck and Pfizer the competitive environment is quite intense. Factors such as the advances in diagnosis of antifungal resistant pathogens and the rising awareness about candidiasis, will provide considerable growth opportunities to candidiasis drugs manufactures. Astellas Pharma, Bayer, Fresenius, Merck, and Pfizer are some of the major companies covered in this report.Read the full report: https://www.reportlinker.com/p05731033 About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place. __________________________ Contact Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001

Cision View original content:http://www.prnewswire.com/news-releases/the-candidiasis-drugs-market-will-register-a-cagr-of-almost-4-by-2023-300791843.html

SOURCE Reportlinker



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store